Human Immunology News Volume 8.40 | Oct 13 2020

May 12, 2022

HIN 8.40 | Oct 13 2020

Human Immunology News by STEMCELL Technologies

Vol. 8.40 – 13 October, 2020

TOP STORY

Anti-GD2
CAR-NKT Cells in Patients with Relapsed or Refractory Neuroblastoma: An Interim Analysis

Investigators report interim results from all three patients enrolled on dose level 1 in a Phase I dose-escalation trial of autologous NKT cells engineered to co-express a GD2-specific chimeric antigen receptor with interleukin-15 in children with relapsed or resistant neuroblastoma.
[Nature Medicine]

Abstract

Virtual Conference Exhibition: Immunology

PUBLICATIONSRanked by the impact factor of the journal

Two Subsets of Stem-Like CD8⁺
Memory T Cell Progenitors with Distinct Fate Commitments in Humans

Researchers identified two previously unrecognized subsets of clonally, epigenetically, functionally, phenotypically and transcriptionally distinct stem-like CD8⁺ memory T cells.
[Nature Immunology]

Abstract

Systemic
Anti–PD-1 Immunotherapy Results in PD-1 Blockade on T Cells in the Cerebrospinal Fluid

The authors evaluated pembrolizumab concentrations and PD-1 blockade on T cells in the cerebrospinal fluid after intravenous administration. Cerebrospinal fluid and blood samples were collected from ten adult patients with high-grade gliomas who were participating in clinical trials of intracranially administered chimeric antigen receptor T cells and intravenous pembrolizumab.
[JAMA Oncology]

Full Article

Single-Cell
RNA Sequencing Highlights the Role of Inflammatory Cancer-Associated Fibroblasts in Bladder Urothelial Carcinoma

Scientists found that tumor cells down regulated MHC-II molecules, suggesting that the downregulated immunogenicity of cancer cells may contribute to the formation of an immunosuppressive microenvironment.
[Nature Communications]

Full Article

A Gene Expression Signature of TREM2^hi
Macrophages and γδ T Cells Predicts Immunotherapy Response

Researchers re-analyzed a publicly available single-cell RNA sequencing dataset of melanoma samples of patients subjected to immune checkpoint therapy and identified a subset of macrophages overexpressing TREM2 and a subset of gammadelta T cells that were both overrepresented in the non-responding tumors.
[Nature Communications]

Full Article

CD19-Specific
CAR-T Cells that Express a PD-1/CD28 Chimeric Switch-Receptor is Effective in Patients with PD-L1 Positive B-Cell Lymphoma

Scientists generated a novel anti-CD19 CAR expressing PD-1/CD28 chimeric switch-receptor. They then conducted a Phase Ib study to evaluate safety and efficacy of CD19-PD-1/CD28-CAR T cells in the treatment of PD-L1⁺ B-cell lymphoma.
[Clinical Cancer Research]

Abstract

Melphalan
and Exportin 1 Inhibitors Exert Synergistic Anti-Tumor Effects in Preclinical Models of Human Multiple Myeloma

Multiple myeloma (MM) cells from newly diagnosed and relapsed/refractory MM patients were also sensitized by XPO1i to melphalan. In NOD/SCID-γ mice challenged with either parental 8226 or U266 MM and melphalan-resistant MM tumors, XPO1i/melphalan combination treatments demonstrated stronger synergistic anti-tumor effects than single-agent melphalan with minimal toxicity.
[Cancer Research]

Abstract

Gfi1 Upregulates C-Myc Expression and Promotes C-Myc-Driven Cell Proliferation

Investigators showed that Gfi1 augmented the expression of c-Myc protein in cells transfected with c-Myc expression constructs. The N-terminal SNAG domain and C-terminal ZF domains of Gfi1, but not its transcriptional repression and DNA binding activities, were required for c-Myc upregulation.
[Scientific Reports]

Full Article

Long-Term Follow-Up of Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy

Between 2009 and 2015, scientists administered 46 CAR T-cell treatments to 43 patients. Patients had relapsed B-cell malignancies of the following types: diffuse large B-cell lymphoma or primary mediastinal B-cell lymphoma, low-grade B-cell lymphoma, or chronic lymphocytic leukemia.
[Immunotherapy]

Abstract

Keep current with the latest in infectious disease research.

REVIEWS

Transcriptional Regulation of Memory B Cell Differentiation

The authors discuss recent advancements regarding the signals and transcription factors regulating germinal center-derived memory B cells development and function.
[Nature Reviews Immunology]

Full Article

INDUSTRY AND POLICY NEWS

TREMFYA^® (Guselkumab) Induces Clinical and Endoscopic Improvements in Patients with Moderately to Severely Active Crohn’s Disease based on Interim Results from Phase II Study

The Janssen Pharmaceutical Companies of Johnson & Johnson announced Phase II interim data from the GALAXI 1 study, which showed TREMFYA^® demonstrated results at week 12 in adult patients with moderately to severely active Crohn’s disease with inadequate response or intolerance to conventional therapies and/or biologics.
[Johnson & Johnson (BusinessWire, Inc.)]

Press Release

Alivio Therapeutics Awarded $3.3 Million from US Department of Defense

Alivio Therapeutics, Inc. announced a $3.3 million US Department of Defense Technology/Therapeutic Development Award to advance its product candidate, ALV-304, for the treatment of inflammatory bowel disease. Alivio’s inflammation-targeting disease immunomodulation approach involves selectively restoring immune homeostasis at inflamed sites in the body, while having minimal impact on the rest of the body’s immune system.
[Alivio Therapeutics, Inc.]

Press Release

FEATURED EVENT

Anti-GD2
CAR-NKT Cells in Patients with Relapsed or Refractory Neuroblastoma: An Interim Analysis

Two Subsets of Stem-Like CD8⁺
Memory T Cell Progenitors with Distinct Fate Commitments in Humans

Systemic
Anti–PD-1 Immunotherapy Results in PD-1 Blockade on T Cells in the Cerebrospinal Fluid

Single-Cell
RNA Sequencing Highlights the Role of Inflammatory Cancer-Associated Fibroblasts in Bladder Urothelial Carcinoma

A Gene Expression Signature of TREM2^hi
Macrophages and γδ T Cells Predicts Immunotherapy Response

CD19-Specific
CAR-T Cells that Express a PD-1/CD28 Chimeric Switch-Receptor is Effective in Patients with PD-L1 Positive B-Cell Lymphoma

Melphalan
and Exportin 1 Inhibitors Exert Synergistic Anti-Tumor Effects in Preclinical Models of Human Multiple Myeloma

Gfi1 Upregulates C-Myc Expression and Promotes C-Myc-Driven Cell Proliferation

Long-Term Follow-Up of Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy

Transcriptional Regulation of Memory B Cell Differentiation

TREMFYA^® (Guselkumab) Induces Clinical and Endoscopic Improvements in Patients with Moderately to Severely Active Crohn’s Disease based on Interim Results from Phase II Study

Alivio Therapeutics Awarded $3.3 Million from US Department of Defense

International Chemical Biology Society (ICBS) 2020 Conference

> See All Events

Postdoctoral Fellowship – Innate Immunity and DNA Repair

Postdoctoral Researcher – Immune Oncology

Scientist Position – Skin Immunology

Research
Positions – Cancer and Immunotherapy

Postdoctoral
Associate – Immune Modulatory Therapies

> See All Jobs